Thyroid nodule. Nontoxic single thyroid nodule
Conditions
Interventions
Intervention 1: Intervention group 1: One tablet of metformin, 500 mg, oral, twice a day, produced by Iran Hormone co, for three months. Intervention 2: Intervention group 2: One tablet of levothyroxi
Treatment - Drugs
Intervention group 1: One tablet of metformin, 500 mg, oral, twice a day, produced by Iran Hormone co, for three months
Intervention group 2: One tablet of levothyroxine, 0.1 mg, oral, once a day, produced by Iran Hormone co, for three months
Intervention group 3: Combination of one tablet of metformin, 500 mg, oral, twice a day, produced by Iran Hormone co and one tablet of levothyroxine, 0.1 mg, oral, once a day, produced by Iran Hormone
Control group: Without usage of any drugs for three months
Sponsors
Vice chancellor for research, Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Female sex, benign thyroid nodule with the size of 0.5-3 cm, euthyroid, negative TPO-Ab, TSH between 0.5-2.5 mU/L, lack of chronic disease, lack of drug usage Exclusion criteria: Chronic usage of any kind of drugs more than three months, thyroid cystic nodules, malignant thyroid nodules
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of thyroid nodule size. Timepoint: The beginning of the study, after three months. Method of measurement: Ultrasonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes of serum TSH level. Timepoint: The beginning of the study, the beginning of the second month, the beginning of the third month, the end of the third month. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfsaneh Talaei
Arak University of Medical Sciences
Outcome results
None listed